SPOTLIGHT -
Can Intranasal Corticosteroids Improve Obstructive Sleep Apnea Syndrome in Children?
A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.
COPD Linked to Three-Fold Greater Mortality Risk in Severe COVID-19 Patients
New data show patients hospitalized with COVID-19 far more frequently suffer from cardiometabolic disease, yet face worse outcomes with COPD.
Tom Gildea, MD: Biopsy Tools in Bronchoscopy
A new study shows that bronchoscopy practice, procedure, and tools vary by facility, and in assessment duration.
Humberto Choi, MD: The Misunderstanding of Non-Cigarette Products
From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.
Robert Wise, MD: Exacerbation Reduction with Aclidinium Bromide
How the LAMA therapy manages one of the integral facets of COPD care.
Humberto Choi, MD: Screening & Treatment Overlap in Lung Cancer, COPD
While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.
Humberto Choi, MD: Vaping Health Misconceptions
How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?
Robert Wise, MD: ASCENT-COPD Takeaways
How the aclidinium bromide trial brings novel perspective to COPD care.
Adriano Tonelli, MD: Improving PH Testing, Therapies
Are diagnostics and drugs optimized for pulmonary hypertension?
Sanjay Sethi, MD: Aclidinium Bromide in COPD
New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.
Sanjay Sethi, MD: Adding LAMA/LABA Options to the Market
What the introduction of aclidinium/formoterol could mean for patients with COPD.
What to Look Forward to in Pulmonary Arterial Hypertension Care
Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.
Why Physicians Need to Get PAH Patients to Echocardiograms
Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.
Diagnosing PAH Early is Difficult, But Critical
Experts advise that primary care physicians give pause next time they treat a patient with unexplained dyspnea—could it be pulmonary hypertension?
Why Do More Females Get Pulmonary Hypertension?
Though the commonly accepted ratio is 3:1 women, longtime clinicians suggest PAH ratio is more likely closer to 4:1.
Improving Dyspnea in Idiopathic Pulmonary Fibrosis
Mary Beth Scholand, MD, outlines the best treatment practices for idiopathic pulmonary fibrosis (IPF) to date and therapies worth investigating in the future.
Nicola Hanania, MD, MS: Combination Therapies in COPD
Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.
Monica Kraft, MD: The New Biologics Entering Asthma
The 2019 CHEST Meeting in New Orleans may be headlined by newly approved therapies including dupilumab and tezepelumab.
The Near Future of Pulmonary Arterial Hypertension Development
Using data registries from initial trials, companies such as Actelion will be looking to expand research beyond the first first or second year of care in patients with PAH.
Alternative Medicine Results Differ Across Asthma Patient Races, Ethnicities
Recent trials have evidenced that minority patient groups in particular are more likely to worsen their primary treatment adherence while embracing alternative medicine measures.
FF/UMEC/VI Versus FF/VI and UMEC/VI: Treatment Effects in COPD
Data from a subgroup analysis of the IMPACT study, which compared inhale triple therapy FF/UMEC/VI to dual therapy FF/VI and UMEC/VI for the treatment of COPD, has been released.
Smoking & Forced Expiratory Flow in COPD
FEF25-75 may be used as a parameter for early detection of beginning small airway obstruction in smokers with normal FEV1/FVC.
Keeping Tabs on PAH Progression Through Comorbidities
Once physicians know if it's the cause of PAH or just simply an overlap, comorbidities have to be closely monitored as disease progression.
Glycopyrrolate Comparable to Tiotropium in Long-Term COPD Deterioration
A twice-daily 50 mcg dose of the nebulized LAMA therapy also had better results for patients with poor FEV1 compared to tiotropium.
Monica Kraft, MD: Finding, Fighting Comorbidities in Severe Asthma
Why delving into the symptoms of the most at-need patients is critical for care.
Rethinking the Asthma-COPD Overlap as a Continuum of Care
Clinical research has begun to distinguish biomarkers for both conditions, research has established their similarities, and therapies are becoming pathway-based. Should asthma-COPD diagnoses be necessary?
Role of Family History in Pediatric Asthma Control
Investigators from the Nationwide Children’s Hospital assessed family history in relation to asthma control in pediatric patients.
Multidisciplinary Discharge Programs Improve Outcomes of Acute Exacerbations of COPD
A COPD care bundle delivered by a multidisciplinary health care team can reduce hospital readmission rates for acute exacerbations of COPD (AECOPD).
Montelukast/Levocetirizine Combination Therapy Yields Effective in Phase 3 Trial
Montelukast/levocetirizine combination therapy demonstrates safety and efficacy in phase 3 clinical trial for the treatment of patients with perennial allergic rhinitis who have mild-to-moderate asthma.
Monica Kraft, MD: Steps Leading Up to Treating Severe Asthma
Before biologics are implemented, what should physicians be doing to ensure asthma control in their patients?
